scorecardresearch
Add as a preferred source on Google
Friday, November 21, 2025
TopicFavipiravir

Topic: favipiravir

Potential Covid drug favipiravir to be available at Rs 103/pill at pharmacies by month-end

A selection of the best news reports, analysis and opinions published by ThePrint this week.

Favipiravir, Japanese drug that’s the new Covid treatment hope your chemist will soon stock

Favipiravir, a drug approved for treating influenza in Japan & China, has shown promise in studies. But many researchers have urged caution in the interpretation of the results. 

Glenmark enrols 150 patients to test favipiravir, the ‘most sought-after drug for Covid’

The dosage frequency of the tablets will be 1,800 mg twice on first day, 800 mg twice on second day, which will then be followed for up to a maximum of 14 days.

India to test Japanese flu drug favipiravir on Covid patients, Glenmark first to start trials

Favipiravir is among the drugs under trial for Covid-19 treatment along with anti-malarial medicine hydroxychloroquine and the Ebola drug remdesivir. 

On Camera

Europe’s sanctions are not the moral compass it paints to be. Look at the EU’s own data

Three years into the war, Europe’s sanctions regime now resembles a policy of managed hypocrisy: Moral rhetoric for public consumption, exemptions for industrial preservation.

At Charcha 2025: Local entrepreneurship, not just big IT, will drive next wave of distributed AI work

While global corporations setting up GCCs in India continue to express confidence in availability of skilled AI engineers, the panel argued that India’s real challenge lies elsewhere.

IAF’s leased KC-135 lands in Agra, American firm’s pilots to man mid-air refueller

India’s refueller fleet comprises six Russian Ilushin-78 tankers, first inducted in 2003, which are facing huge maintenance and serviceability issues.

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.